Aurobindo Pharma
Aurobindo Pharma USA
279 Princeton Hightstown Road
East Windsor
New Jersey
08520
United States
Tel: 866-850-2876
Website: http://www.aurobindousa.com/
59 articles about Aurobindo Pharma
-
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
-
There is a noted discrepancy between the price the U.S. government has agreed to pay Merck for the drug and the actual manufacturing costs.
-
COVAXX and Aurobindo Pharma Announce COVID-19 Vaccine Partnership
12/24/2020
Aurobindo Pharma has exclusive rights to develop and commercialize UB-612 in India and to UNICEF and non-exclusive rights in other select emerging markets Expected to support up to 480 million doses of UB-612 for India and other countries Agreement leverages Aurobindo Pharma’s existing development, commercial and manufacturing infrastructure
-
Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF
12/24/2020
COVAXX's UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution Agreement leverages Aurobindo's existing development, commercial and manufacturing infrastructure Phase 2/3 clinical trials by COVAXX t
-
Under terms of the deal, Aurobindo would pay $900 million upfront with an additional $100 million in milestone payments. However, in a filing with the Securities and Exchange Commission, the company announced it had terminated that agreement.
-
Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio
3/1/2019
Spectrum Pharmaceuticals, Inc. completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India.
-
Acrotech Biopharma, a New Jersey-based subsidiary of Aurobindo Pharma USA, is buying Henderson, Nevada-based Spectrum Pharmaceuticals’ seven FDA-approved hematology/oncology products.
-
The U.S. Food and Drug Administration issued a voluntary recall of a medication to treat high blood pressure due to trace amounts of a carcinogen being found within some lots of the drug.
-
Amidst Strong Quarterly Growth, Novartis Receives FDA Complete Response Letter for Canakinumab
10/18/2018
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular ris... -
Alcon, the Novartis eye care business, is leaving its longtime home of Texas for Switzerland. The company said it will move its corporate headquarters from Fort Worth to Geneva following the spinoff from Novartis.
-
Today Narasimhan and Novartis announced they were selling U.S. dermatology and generic drug assets, parts of its Sandoz division, to India’s Aurobindo Pharma for up to $1 billion. The deal includes approximately 300 products.
-
In January, it was announced that five healthcare systems were launching a not-for-profit generic drug company. That company now has a name, Civica Rx.
-
Ironwood Pharmaceuticals, located in Cambridge, Massachusetts, released its second-quarter financial report and updated its business activities. Key among the announcements was the termination of a license deal with AstraZeneca for its lesinurad franchise.
-
Aurobindo Pharma Launches Oral Contraceptives
5/15/2018
Aurobindo Pharma Limited has launched Mili™ and Tri-Mili™ lines of oral contraceptive tablets.
-
Novartis’ generics division, Sandoz, has been struggling in the face of intense pricing pressure. As a result, Novartis has been looking to sell off some of its Sandoz businesses.
-
Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.
-
Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation
5/3/2018
Ironwood Pharmaceuticals, Inc. announced that the companies have reached an agreement with Aurobindo Pharma Ltd.
-
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
-
The portfolio consists of acute, chronic and oncology products.
-
Aurobindo Eyes U.S. Plant in New Jersey As Trump Calls for Local Drug Production
2/10/2017